COR · 10-Q · 2026Q2 · Full report

Operating Expense Trends

Cencora, Inc. · 2026-08-05 · Importance 47 · Surprise 48 · In source text

Total operating expenses increased 21.9% year over year to $2.5 billion in the June 2026 quarter and 22.5% to $7.2 billion for the nine-month period. Distribution, selling, and administrative expense increased 27.5% to $2.1 billion in the quarter and 24.5% to $5.9 billion year to date, primarily because of OneOncology and RCA. Acquisition and divestiture-related expenses increased to $113.1 million in the quarter and $355.7 million year to date, including $152.7 million of RCA and OneOncology equity-unit adjustments year to date. A $102.0 million opioid-liability reduction and an $86.8 million derivative lawsuit settlement credit reduced litigation expense in 2026, partially offsetting higher acquisition-related costs.

Key facts

• Total operating expenses increased by $447.6 million, or 21.9%, from the prior year quarter and by $1,329.5 million, or 22.5%, from the prior year nine-month period. source
• Distribution, selling, and administrative expense was $2,132.5 million for the three months ended June 30, 2026 and $1,672.9 million for the three months ended June 30, 2025, a 27.5% increase. source
• Total segment operating income was $1,238.1 million for the three months ended June 30, 2026 and $1,058.3 million for the three months ended June 30, 2025, a 17.0% increase. source
• Operating income was $1,120.2 million for the three months ended June 30, 2026 and $867.7 million for the three months ended June 30, 2025, a 29.1% increase. source
• Depreciation and amortization expense was $269.5 million for the three months ended June 30, 2026 and $254.0 million for the three months ended June 30, 2025, a 6.1% increase. source
• Inflation in the global and U.S. economies has impacted certain operating expenses, including fuel costs. source

Impact estimates